Research Paper Volume 16, Issue 17 pp 12392—12413
RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway
Figure 2. RPL22L1 was an independent variable for predicting OS in LUAD. (A) OS. (B) PFS. (C) DSS. (D) Forest plot display of the results of the multivariate Cox regression analysis of RPL22L1 and clinical characteristics in LUAD. (E) Nomograms were developed to estimate the likelihood of OS at 1-, 3-, and 5-year intervals in patients with LUAD.